Merck/Moderna cancer vaccine cuts melanoma death or recurrence risk by 42%, shares fall Hong Kong Standard 14h Moderna Pharma All sources
Merck KGaA spends $1.3bn to buy siRNA specialist Silence Therapeutics Pharmaceutical Technology 3d Silence Therapeutics Pharma Biotechnology All sources
Merck opens new semiconductor materials facility in Korea The Korea Times 1d Merck Pharma IT All sources
Merck and Moderna Prepare FDA Filing for Personalized mRNA Melanoma Vaccine Paired with Keytruda After Phase 3 Results Medical Daily 3d KEYTRUDA Moderna Pharma
Consiliul Concurenței, intervenție fermă pe piața farmaceutică: Posibil abuz de poziţie dominantă al grupului Merck Sharp & Dohme NewMoney.ro 1h
Consiliul Concurenţei, în inspecţie inopinată la grupul de firme Merck. Ar fi restricţionat accesul DONA la vânzarea unor medicamente Economica.net 1h
Consiliul Concurenței investighează un posibil abuz de poziție dominantă al Grupului Merck Sharp & Dohme pe piața farmaceutică Profit.ro 1h
Moderna stock plummets even after data confirm cancer vaccine with Merck met key endpoints in melanoma trial Boston Globe 2h Article paywall
Gilead spends $1.28bn on PepStar’s potential Icotyde rival Pharmaceutical Technology 2h Gilead Sciences Biotech
Bottom of the Hill sold to biotech executive, will stay open as S.F. music venue San Francisco Chronicle 12h Biotech Biotechnology
Amgen vs. Eli Lilly: Does the GLP-1 mania make LLY stock a better buy in 2026? The Motley Fool 15h Eli Lilly Amgen Biotechnology
